Literature DB >> 19150563

Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality.

Mike M Nguyen1, Inderbir S Gill.   

Abstract

PURPOSE: We determined the relationship between the prevalence of metastasis at presentation and cancer specific mortality with tumor size in renal cancer cases using a large cancer database.
MATERIALS AND METHODS: The Surveillance, Epidemiology and End Results data set was analyzed for renal tumors diagnosed from 1998 to 2003. A total of 24,253 patients were included. The prevalence of metastasis and cancer specific survival as a function of tumor size were evaluated using linear and nonlinear curve fitting methods. Metastatic cases with tumors 2.5 cm or less were individually reconfirmed case by case for accuracy.
RESULTS: Increasing tumor size correlated with a higher prevalence of metastasis at diagnosis (range 1.4% for tumors 1 cm or less to 50.9% for tumors greater than 15 cm). Five-year cancer specific mortality in treated patients was also closely related to tumor size (range 3.5% for tumors 1 cm or less to 50.9% for tumors greater than 15 cm). In each instance the relationship was sigmoidal rather than linear and it was best modeled using a quadratic function. The most rapid increase in the prevalence of metastasis and mortality was noted for tumors 4 to 12 cm. In treated patients with tumors 1 cm or less, 1.1 to 2, 2.1 to 3 and 3.1 to 4 the prevalence of metastasis at diagnosis was 1.4%, 2.5%, 4.7% and 7.4%, and the 5-year cancer specific mortality rate was 3.5%, 3.8%, 4.1% and 5.3%, respectively.
CONCLUSIONS: In cases of renal cancer the prevalence of metastasis at presentation and 5-year cancer specific mortality increase in a nonlinear sigmoidal relationship with tumor size.

Entities:  

Mesh:

Year:  2009        PMID: 19150563     DOI: 10.1016/j.juro.2008.11.023

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  27 in total

1.  [Partial nephrectomy. Rationale and limitations of an organ-preserving approach].

Authors:  J Casuscelli; C Gratzke; C G Stief; M Staehler
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

2.  Responses: Re: Csaba Berczi, Ben Thomas, Zsolt Bacso, Tibor Flasko. Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 2016 (Epub ahead of print).

Authors:  Csaba Berczi
Journal:  Int Urol Nephrol       Date:  2017-01-09       Impact factor: 2.370

3.  Re: Csaba Berczi, Ben Thomas, Zsolt Bacso, Tibor Flasko. Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 2016 (Epub ahead of print).

Authors:  Matthew J Watson; Abhinav Sidana; Eric A Singer; Gopal N Gupta; Ardeshir R Rastinehad; Srinivas Vourganti; Gennady Bratslavsky; Adam R Metwalli
Journal:  Int Urol Nephrol       Date:  2016-10-27       Impact factor: 2.370

4.  Thermoablation of Renal Masses: The Urologist's Perspective.

Authors:  Phillip H Abbosh; Sam B Bhayani
Journal:  Semin Intervent Radiol       Date:  2011-12       Impact factor: 1.513

Review 5.  Review of renal cell carcinoma and its common subtypes in radiology.

Authors:  Gavin Low; Guan Huang; Winnie Fu; Zaahir Moloo; Safwat Girgis
Journal:  World J Radiol       Date:  2016-05-28

6.  Evaluation of renal masses with contrast-enhanced ultrasound: initial experience.

Authors:  Scott Gerst; Lucy E Hann; Duan Li; Mithat Gonen; Satish Tickoo; Michael J Sohn; Paul Russo
Journal:  AJR Am J Roentgenol       Date:  2011-10       Impact factor: 3.959

Review 7.  Solid renal masses: what the numbers tell us.

Authors:  Stella K Kang; William C Huang; Pari V Pandharipande; Hersh Chandarana
Journal:  AJR Am J Roentgenol       Date:  2014-06       Impact factor: 3.959

Review 8.  Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.

Authors:  Marc C Smaldone; Alexander Kutikov; Brian L Egleston; Daniel J Canter; Rosalia Viterbo; David Y T Chen; Michael A Jewett; Richard E Greenberg; Robert G Uzzo
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

Review 9.  p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Authors:  Aidan P Noon; Nikolina Vlatković; Radosław Polański; Maria Maguire; Howida Shawki; Keith Parsons; Mark T Boyd
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

Review 10.  [Active surveillance: concept for renal cell carcinoma?].

Authors:  I Tsaur; D Schilling; A Haferkamp
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.